Transplant Complications Drug Development Pipeline Review, 2018

Transplant Complications Drug Development Pipeline Review, 2018

  • GBI Research
  • November 2018
  • Pharmaceutical
  • 173 pages

Report Description

1
1

This report provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), liver transplant rejection, kidney transplant rejection and lung transplant rejection and features dormant and discontinued products.

GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment consists of immunosuppressants. There are 125 products in development for GVHD.

Organ transplantation replaces an injured or diseased organ with a healthy one. Following a transplant, the immune system may consider the transplanted tissue as foreign and work against it. Patients can develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, blocking organ rejection and facilitating a successful transplant. There are 18 products in development for liver transplant rejection, 49 products in development for kidney transplant rejection and 12 products in development for lung transplant rejection.

Molecular targets acted on by products in development for transplantation complications include tyrosine kinases, caspases and chemokine receptors. Companies operating in this pipeline space include Medeor Therapeutics, Amgen and Novartis.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Have query on this report?

Make an Enquiry

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7

2 Introduction 9
2.1 Transplant Complications Report Coverage 9
2.2 Graft Versus Host Disease (GVHD) - Overview 9
2.3 Liver Transplant Rejection - Overview 9
2.4 Kidney Transplant Rejection - Overview 9
2.5 Lung Transplant Rejection - Overview 9

3 Therapeutics Development 10
3.1 Graft Versus Host Disease (GVHD) 10
3.2 Liver Transplant Rejection 23
3.3 Kidney Transplant Rejection 27
3.4 Lung Transplant Rejection 34

4 Therapeutics Assessment 37
4.1 Graft Versus Host Disease (GVHD) 37
4.2 Liver Transplant Rejection 47
4.3 Kidney Transplant Rejection 53
4.4 Lung Transplant Rejection 60

Table 1: Number of Products under Development for Graft Versus Host Disease (GVHD) 10
Table 2: Number of Products under Development by Companies, Graft Versus Host Disease (GVHD) 12
Table 3: Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 15
Table 4: Products under Development by Companies, Graft Versus Host Disease (GVHD) 16
Table 5: Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 22
Table 6: Number of Products under Development for Liver Transplant Rejection 23
Table 7: Number of Products under Development by Companies, Liver Transplant Rejection 24
Table 8: Number of Products under Development by Universities/Institutes, Liver Transplant Rejection 25
Table 9: Products under Development by Companies, Liver Transplant Rejection 26
Table 10: Products under Development by Universities/Institutes, Liver Transplant Rejection 27
Table 11: Number of Products under Development for Kidney Transplant Rejection 28
Table 12: Number of Products under Development by Companies, Kidney Transplant Rejection 29
Table 13: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection 30
Table 14: Products under Development by Companies, Kidney Transplant Rejection 31
Table 15: Products under Development by Universities/Institutes, Kidney Transplant Rejection 33
Table 16: Number of Products under Development for Lung Transplant Rejection 34
Table 17: Number of Products under Development by Companies, Lung Transplant Rejection 35
Table 18: Products under Development by Companies, Lung Transplant Rejection 36
Table 19: Number of Products by Stage and Target, Graft Versus Host Disease (GVHD) 38
Table 20: Number of Products by Stage and Mechanism of Action, Graft Versus Host Disease (GVHD) 41
Table 21: Number of Products by Stage and Route of Administration, Graft Versus Host Disease (GVHD) 45
Table 22: Number of Products by Stage and Molecule Type, Graft Versus Host Disease (GVHD) 46
Table 23: Number of Products by Stage and Target, Liver Transplant Rejection 48
Table 24: Number of Products by Stage and Mechanism of Action, Liver Transplant Rejection 49
Table 25: Number of Products by Stage and Route of Administration, Liver Transplant Rejection 51
Table 26: Number of Products by Stage and Molecule Type, Liver Transplant Rejection 52
Table 27: Number of Products by Stage and Target, Kidney Transplant Rejection 54
Table 28: Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection 56
Table 29: Number of Products by Stage and Route of Administration, Kidney Transplant Rejection 58
Table 30: Number of Products by Stage and Molecule Type, Kidney Transplant Rejection 59
Table 31: Number of Products by Stage and Target, Lung Transplant Rejection 61
Table 32: Number of Products by Stage and Mechanism of Action, Lung Transplant Rejection 62
Table 33: Number of Products by Stage and Route of Administration, Lung Transplant Rejection 64
Table 34: Number of Products by Stage and Molecule Type, Lung Transplant Rejection 65
Table 35: Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc 66
Table 36: Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc 66
Table 37: Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc 67
Table 38: Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc 67
Table 39: Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH 68
Table 40: Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc 68
Table 41: Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc 69
Table 42: Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc 70
Table 43: Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc 70
Table 44: Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Co 71
Table 45: Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc 72
Table 46: Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA 72
Table 47: Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biotechnology Ltd 72
Table 48: Graft Versus Host Disease (GVHD) - Pipeline by Cellective BioTherapy Inc 73
Table 49: Graft Versus Host Disease (GVHD) - Pipeline by CSL Ltd 73
Table 50: Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd 74
Table 51: Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc 74
Table 52: Graft Versus Host Disease (GVHD) - Pipeline by Elsalys Biotech SA 75
Table 53: Graft Versus Host Disease (GVHD) - Pipeline by enGene Inc 75
Table 54: Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd 76
Table 55: Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd 76
Table 56: Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc 77
Table 57: Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd 77
Table 58: Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc 78
Table 59: Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp 79
Table 60: Graft Versus Host Disease (GVHD) - Pipeline by Inspyr Therapeutics Inc 79

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074